Kuaishou Signs Global Deal with AMRAGlobal Licensing Agreement • March 30th, 2023
OncoCyte Corporation and The Wistar Institute Enter into Global Licensing AgreementGlobal Licensing Agreement • January 27th, 2016 • OncoCyte Corp • In vitro & in vivo diagnostic substances
This licensing agreement builds on existing collaborations between OncoCyte and Wistar including previously announced sponsored research agreements entered into to develop and test potential lung cancer biomarkers identified by Dr. Louise Showe. In August 2015, Wistar and OncoCyte announced an expanded agreement to continue their collaboration.
Awakn Life Sciences Enters Global Licensing Agreement For Proprietary Sublingual S- Ketamine Formulation With LTSGlobal Licensing Agreement • December 20th, 2023
Toronto, Ontario--(Newsfile Corp. - December 20, 2023) - Awakn Life Sciences Corp. (NEO: AWKN) (OTCQB: AWKNF) (FSE: 954) ("Awakn"), a clinical-stage biotechnology company developing Medication-Assisted Treatments to treat addiction with a near-term focus on Alcohol Use Disorder (AUD), announces it has signed a global licensing agreement with LTS Lohmann Therapie-Systeme AG ("LTS"), a leading pharmaceutical technology company. The agreement is for a proprietary S-ketamine formulation, administered sublingually via an oral thin film (OTF). Awakn will have global exclusivity of its use in the treatment of Addiction, Anxiety Disorders, and Eating Disorders.
THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION AS DEFINED UNDER THE MARKET ABUSE REGULATION (EU) NO. 596/2014. UPON PUBLICATION OF THIS ANNOUNCEMENT THIS INFORMATION IS NOW CONSIDERED IN THE PUBLIC DOMAIN. Mereo BioPharma and Oncologie Enter into...Global Licensing Agreement • January 13th, 2020 • Mereo Biopharma Group PLC • Pharmaceutical preparations
London, Redwood City, Calif., and Boston, January 13, 2020 - Mereo BioPharma Group plc (NASDAQ: MREO, AIM: MPH), “Mereo” or the “Company,” and Oncologie, Inc. (“Oncologie”) today announced a global license agreement (the “License Agreement”) for the development and commercialization of navicixizumab, an anti-DLL4/VEGF bispecific antibody currently being evaluated in an ongoing Phase 1b study in combination with paclitaxel in patients with advanced heavily pretreated ovarian cancer. Navicixizumab previously completed a Phase 1a monotherapy study in patients with various types of refractory solid tumors and is one of two product candidates Mereo acquired through its 2019 merger with OncoMed Pharmaceuticals, Inc. In October 2019, the U.S. Food and Drug Administration (“FDA”) granted Fast Track designation to navicixizumab and has agreed in principle on the design of a study that could potentially support accelerated approval for navicixizumab in a heavily pretreated, platinum-resistant ov
ContractGlobal Licensing Agreement • October 25th, 2011
Tokyo, Japan, October 20, 2011: Oncolys BioPharma Inc., Bristol-Myers Squibb Company (NYSE:BMY) and Yale University have received a 2011 Deals of DistinctionTM Award from the Licensing Executives Society (U.S.A. and Canada) in recognition of an agreement for the development of an investigational HIV compound. The compound is now known as BMS-986001/OBP-601, a once-a-day, orally available nucleoside reverse transcriptase inhibitor (NRTI) in Phase II development. The transaction was selected as winner of the Industry-University-Government Interface (IUGI) category of the Deals of DistinctionTM, which annually honor outstanding licensing and intellectual property-related agreements.
